**Supplemental Table 1. Numerical growth ratesa**

**Col. 1 2 3 4 5 6 7 8 9**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Figure | Doubling Time Baseline, LD  (Months) | Doubling Time  Baseline 2D (Area)  (Months) | DT\_B  (Sum LD) | DT\_B  (Sum 2D) | Fast  Sum (LD) | DT on Treatment  Row 1: LD  Row 2: Area (2D) | Success | PK mg/L |
| 2A | 3.7,4.1  Med: 3.9 | 4.0,2.3  Med: 3.1 | 3.9 | 2.9 | Y | FL,-6.7  -70,-3.5 | **Y**  **SD 5.5** | 46.7 |
| 2B | 1.8,2.6,3.6  Med: 2.6 | 1.7,1.8,1.5  Med: 1.7 | 2.6 | 1.6 | Y | -6.4,-9.9,-61.8  -2.7,-36.1,-214.4 | **Y**  **SD 7.4** | 49.6 |
| 2C | 2.0  Med: 2.0 | 0.9  Med: 0.9 | 2.0 | 0.9 | Y | 2.8  1.3  Decrease size post 2nd cycle | **Y**  **SD 9.2** | 33.2 |
| 2F | 4.5,4.4,7.4  Med: 4.5 | 1.7,3.4,3.3  Med: 3.3 | 4.8 | 3.1 | Y | 11.9,6.0,9.5  6.7,13.3,-33.3 | UNK  SD 7.3 | 25.1 |
| 2E | 6.2,9.1,1.5  Med: 6.2 | 3.3,-40.2,0.9  Med: 0.9 | 4.0 | 3.0 | Y | -4.9,-10.5,-3.2  -4.9,-1.4,-1.0 | N  NL 3.4 | 49.8 |
| 3F | 4.6,3.5, FL  Med: 4.6 | 2.2,1.3,3.5  Med: 2.2 | 5.4 | 1.7 | Y | -6.0, -2.9,-5.3  -2.8,-1.4,-5.3 | N  NL 1 | -- |
| 3Eb | 1.8,0.5,1.0  Med:1.0 | 1.1,0.3,0.5  Med: 0.5 | 0.8 | 0.4 | Y | 4.8,1.2,1.2  3.4,0.6,0.6 | N  PD 1.3 | -- |
| 3D | FL,FL,2.3,4.3  Med: Undef | -8.9,10.1,1.2,1.1  Med: 1.2 | 7.6 | 3.2 | Y | Adverse Event | N  DOD/PDc 1.6 | -- |
| 2D | 34.9,-19.7  Med: 7.6 | 16.7, 3.6  Med: 10.2 | -156.2 | 7.5 | N | -2.5, -1.6  -0.9, -1.1 | **Y**  **PR 5.5** | 47.4 |
| 3A | FL,-2.3,1.6,8, FL  Med: Undef | 7.4,-3.8,0.9,3.5,4.7  Med: 2.2 | FL | 5.8 | N | FL,FL,-10.2,-4.3,-5.9  -8.3,-6.3,-2.3,-1.9,-3.8 | UNK  DOD/PDc 8.6 | -- |
| 3C | 28.3,110.3  Med: 69.3 | -71.1,111.0  Med: 20.0 | 43.2 | -199.3  (FL) | N | 95.2,25.5  15.7,10.4 | UNK  PD 3.75 | 29.5 |
| 3B | FL, FL  Med: FL | 5.2, 9.6  Med: 7.4 | FL | 8.0 | N | FL, 10.2  FL,51.0 | UNK  SD 13.1 | 60.3 |

a 13 of the 133 measurements after the first baseline had the longest dimension shorter than the perpendicular, likely related to whether the original orientation was maintained for the dimensions. For consistency, we used the longest dimension reported for each lesion even if recorded as the perpendicular measurement. Slow was determined by doubling time of 10.8 months or longer based on sum of LD (growth rate of 6.1% or less during 28 days). FL=Flat. NL=New Lesion.

b Missing value for target right lung lesion #1 at first evaluation and this lesion was omitted.

c Patient died without progressive disease.